此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

与使用 Sudoscan® 的健康受试者相比,纤维肌痛患者小纤维神经病变患病率的初步研究 (NEFI)

2026年11月13日 更新者:University Hospital, Clermont-Ferrand

Fibromyalgia (FM) is characterized by chronic diffuse pain and affects 0.5 to 5% of the population, with a higher prevalence in women1. This condition is characterized by joint and muscle pain, also associated with fatigue, migraine, sleeps disorders, depression and irritable bowel syndrome2. The presentation of these various symptoms varies greatly from one patient to another, with great heterogeneity in clinical, physical, social, psychological and therapeutic responses. . A recent parliamentary inquiry report called for recognition of the disease and recommended to build a unified care path for patients; a collective expertise is led by INSERM to help in patient care. Faced with the heterogeneity of FM, several international studies have attempted to identify subgroups of patients based essentially on clinical symptoms of the disease3-8, including a recent Korean study of 313 patients9, which suggested four groups, but with methodological limitations, not taking into account the new criteria10 for evaluating FM.

Recent studies have also shown that there is a peripheral neuropathic component in the mechanisms of this pathology, demonstrated by a decrease in the density of the epidermal nerve fibers11-12, called small fiber neuropathy (SFN) neuropathy. It is an attack of small sensory and sympathetic nerve fibers, causing pain, paresthesia as well as disturbances of the autonomous system. Other studies also suggested that a significant proportion of patients diagnosed with fibromyalgia had SFN, demonstrated by cutaneous biopsy13-14 or confocal microscopy of the cornea15. A new device, the Sudoscan®, makes it possible to detect a SFN much simpler, faster and less invasive than the technique of ophthalmology or biopsy. Although this Sudoscan® test has been used extensively in conditions such as diabetes16-19, no study has been used to assess the presence of SFN in FM.

The aim of this pilot study is to identify the prevalence of SFN in FM patients, using this new non-invasive device, in order to have a better defined representation of the prevalence of small-fiber neuropathy in an FM population compared to a group of healthy volunteer matched in age, sex, BMI and by menopausal status for women.

研究概览

地位

完全的

条件

干预/治疗

详细说明

Only one visit (2 to 3h) :

Inclusion of the patient Clinical examination ; evaluation of pain for FM patients Measurement of the electrochemical conductance of the hands and feet using Sudoscan® Evaluation of quality of life, anxiety, depression, sleep quality, fatigue, catastrophizing and social precarity End of study

研究类型

介入性

注册 (实际的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Clermont-Ferrand、法国、63003
        • CHU Clermont-Ferrand

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • - Patient over 18 years of age and under 65 years of age,
  • Male or female patient,
  • Patient with fibromyalgia (according to the ACR criteria of 2016),
  • Cooperation and understanding sufficient to comply with the requirements of the study,
  • Acceptance of written consent,
  • Affiliation to the French Social Security system.

Inclusion criteria healthy subjects:

  • Subject of more than 18 years,
  • Woman or man,
  • Healthy voluntary non-painful subjects matched by age (+/- 5 years), by sex, by BMI (+/- 10%) and by menopausal status for women,
  • Cooperation and understanding sufficient to comply with the requirements of the study,
  • Acceptance of written consent,
  • Affiliation to the French Social Security system,
  • Registration or acceptance of registration in the National Register of Volunteers participating in research.

Exclusion Criteria:

  • Exclusion criteria patients:
  • Patient with a physical inability to place the palms of the hands or the soles of the feet on the electrodes of Sudoscan®,
  • Patient with a medical and / or surgical history judged by the investigator or his representative to be incompatible with the test (in particular a disease known to give neuropathies of small fibers: diabetes, Gougerot-Sjögren's disease, vasculitis, sarcoidosis, chronic ethylism ...),
  • Pregnant or nursing woman
  • Patient participating in another clinical trial, or in a period of exclusion, or having received a total amount of compensation in excess of EUR 4500 over the 12 months preceding the start of the trial,
  • Patient benefiting from a measure of legal protection (curatorship, guardianship, safeguard of justice ...),
  • Patient not affiliated to the French Social Security system.

Exclusion criteria healthy subjects :

  • Physical inability to place the palms of the hands or the soles of the feet on the electrodes of Sudoscan®.
  • Medical and / or surgical history judged by the investigator or his representative to be incompatible with the test,
  • Pregnant or nursing woman
  • Participating in another clinical trial, or within the exclusion period, or having received a total amount of compensation in excess of EUR 4500 over the 12 months preceding the start of the trial,
  • Cooperation and an understanding that does not permit strict compliance with the conditions laid down in the Protocol,
  • Benefiting from a measure of legal protection (curatorship, guardianship, safeguard of justice ...),
  • Not affiliated to the French Social Security system.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:FM patients

50 fibromyalgia patients/50 healthy subjects

Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.

有源比较器:Healthy subjects

50 fibromyalgia patients/50 healthy subjects

Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Measure of the electrochemical conductance (µS) using Sudoscan®
大体时间:at day 1

Evaluation of the prevalence of fibromyalgia patients with small fibro neuropathy in comparison with healthy volunteers by measuring the electrochemical conductance of the palms of the hands (middle right and left hands) and feet (middle right and left) in μS using Sudoscan®.

at day 1

次要结果测量

结果测量
措施说明
大体时间
Biometric criteria
大体时间:at day 1

Collection of the age in years

at day 1
Biometric criteria
大体时间:at day 1

Collection of sex, (male or female)

at day 1
Biometric criteria
大体时间:at day 1

Collection weight in kilograms, height in meters, weight and eight will be combined to report BMI in kg/m²,

at day 1
Biometric criteria
大体时间:at day 1

phototype Fitzpatrick classification

at day 1
Numerical scale
大体时间:at day 1

This scale allows the patient to note pain on a graduation with a minimum score of 0 and a maximum score of 10. Higher value represent worse outcome.

at day 1
Brief Pain Inventory
大体时间:at day 1

The BPI gives two main scores: a pain severity score and a pain interference score

at day 1
Fibromyalgia Impact Questionnaire
大体时间:at day 1

The revised FIQ questionnaire is a 10-item self-questionnaire that assesses the impact of fibromyalgia. The first item is subdivided into 10 questions that assess the impact of the disease in everyday life

at day 1
Quality of life (SF-12)
大体时间:at day 1

12 questions and an index is determined for both physical and mental health (0-100). Higher scores indicate greater physical and mental health

at day 1
Anxiety and Depression (HAD)
大体时间:at day 1

The HAD scale is a 14-item self-administered questionnaire completed by the patient. These items are divided into two subscales: 7 items to assess depression and 7 items to assess anxiety. Higher value represent worse outcome.

at day 1
Depression (Beck Depression Inventory)
大体时间:at day 1

Each item consists of 4 sentences corresponding to 4 degrees of increasing intensity of a symptom: from 0 to 3. In the counting, it is necessary to take into account the highest rating chosen for the same series. The overall score is obtained by adding the scores of the 13 items. The range of the scale is from 0 to 39. The higher the score, the more the subject is depressed.

at day 1
Pittsburgh Sleep Quality Index
大体时间:at day 1

19-item self-administered questionnaire used to assess the quality of sleep. Higher value represent worse quality of sleep.

at day 1
Chronic fatigue Severity Scale
大体时间:at day 1

9-item self-questionnaire to assess the patient's fatigue intensity. The patient is asked to circle a number from 1 to 7 for each question, a low value representing a low intensity. Higher value represents worse fatigue.

at day 1
Pain Catastrophizing Scale
大体时间:at day 1

This questionnaire consists of 13 items. The patient will have to indicate how much he has thoughts or emotions when he feels pain by giving a score between 0 and 4, 0: not at all, 4: all the time. The final score is the sum of the scores for each question. Higher value represent worse outcome.

at day 1
Assessment of socio-professional category, precariousness and health inequalities (Score EPICES).
大体时间:at day 1

The EPICES questionnaire consists of 11 binary questions (yes / no) to calculate an individual score indicating the precariousness and inequalities of health ranging from 0 to 100. Higher value represent worse outcome.

at day 1
Measure of the electrochemical conductance (µS) using Sudoscan®
大体时间:at day 1

Assess the reproducibility (2 passes) of Sudoscan® in each participant: measurement of the electrochemical conductance of the palms of the hands (middle right and left hands) and feet (middle right and left) in μS using the Sudoscan®, 30 minutes after the first measurement.

at day 1

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Gisèle PICKERING、University Hospital, Clermont-Ferrand

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2017年11月6日

初级完成 (实际的)

2018年3月14日

研究完成 (实际的)

2018年3月14日

研究注册日期

首次提交

2017年11月8日

首先提交符合 QC 标准的

2017年11月15日

首次发布 (实际的)

2017年11月20日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2017年12月1日

更多信息

与本研究相关的术语

其他研究编号

  • CHU-362

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.